{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000106","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.444015+00:00","generated_at":"2026-05-17T02:59:53.516977+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"confidence":"high","headline":"Cartesian Therapeutics eliminates CSO role, terminates Dr. Christopher Jewell effective Nov 14, 2025","bullets":["CSO position eliminated; Dr. Christopher Jewell terminated without cause effective November 14, 2025.","Separation agreement signed Oct 20, 2025 provides 12 months salary and pro-rated bonus eligibility.","Dr. Jewell releases all claims against the company in exchange for severance benefits."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000106","json":"https://secwatch.observer/filing/0001453687-25-000106.json","markdown":"https://secwatch.observer/filing/0001453687-25-000106.md","text":"https://secwatch.observer/filing/0001453687-25-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000106/0001453687-25-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000106/rnac-20251015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:59:53.516977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}